Moderna stock ( NYSE:MRNA ) rose to prominence during the pandemic owing to its coronavirus vaccine. The stock price followed suit, rising 434% by 2020. However, demand for vaccination stocks has declined since then. Moderna’s stock ( NYSE:MRNA ) has dropped.
Simultaneously, another biotech startup, Axsome Therapeutics (AXSM), is receiving its due. So far, Axsome stock (NASDAQ:AXSM) has resisted the bad market . This is when the company’s initial items are released.
Regardless of current stock performance, both firms have bright possibilities for the future. The issue now is, which of these dynamic biotech businesses is the best investment right now?
The Moderna Stock Argument
So far this year, Moderna stock ( NYSE:MRNA ) has fallen by half. Yes, Moderna is now making billions of dollars from their coronavirus vaccine . However, investors are concerned about vaccination or booster sales in a post-pandemic scenario.
These fears may be exaggerated. According to Moderna, after the epidemic, the vaccine business in the United States may be worth up to $13 billion . International markets might contribute to this. These figures do not lead to vaccine sales exceeding this year’s $21 billion forecast. However, they ...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube
PressReach Disclaimer .